Results 51 to 60 of about 1,389,538 (204)
Potential value of slow‐wave sleep in management of chronic insomnia disorder
Abstract Chronic insomnia disorder (CID), acknowledged as the most common sleep disorder, has traditionally been diagnosed and managed with a focus on reducing sleep onset latency and extending total sleep duration. However, the critical importance of slow‐wave sleep (SWS), a key indicator of objective sleep quality, has been largely overlooked in ...
Liping Zhang +4 more
wiley +1 more source
Orexin or hypocretin; a peptide that resembles the molecular structure of the gastric peptide secretin, was discovered in 1996 by two independent groups of researchers.
Selena E. Bartlett +5 more
core +1 more source
Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli +7 more
wiley +1 more source
Objective: Caffeine is a non-selective adenosine receptor antagonist with pro-arousal and pro-sympathetic nervous system excitatory effects, and these pharmacological effects fit well with the physiological functions of orexin.
Yan Li +5 more
doaj +1 more source
Gut microbiota as a novel therapeutic target for eating disorders and obesity
The graphical abstract highlights the bidirectional interaction between the gut microbiota and central homeostatic and hedonic mechanisms regulating food intake, which contributes to overweight and obesity. It also illustrates emerging microbiota‐based biomarkers and therapeutic strategies (including prebiotics, probiotics, postbiotics, synbiotics and ...
Solveiga Samulėnaitė +5 more
wiley +1 more source
In Silico to In Cerebro-Development of the Orexin Receptor Antagonist "Photorexant" for Photomodulation In Vitro and in Mouse Brains. [PDF]
Following a structure‐based design approach, photoswitchable derivatives of the FDA‐approved drug suvorexant were designed, docked, synthesized, and characterized pharmacologically at the orexin 1 and 2 receptors (OX1R and OX2R). Optimized “photorexant” showed up to an 11‐fold difference in IC50 between photoisomers, enabled dynamic and reversible ...
Angermann M +10 more
europepmc +2 more sources
Novel targets in headache: A narrative review
Abstract Objectives/Background This narrative review summarizes novel applications for the use of calcitonin gene‐related peptide (CGRP)‐targeted therapies that go beyond migraine, the latest updates with respect to targeting pituitary adenylate cyclase‐activating peptide (PACAP) as therapeutic in migraine, as well as exploring other more recently ...
Adriana Della Pietra +5 more
wiley +1 more source
ABSTRACT Background Falls are the leading cause of injury in older adults. Sedative‐hypnotic use is a known risk factor, but their use for insomnia continues to be common. Dual orexin receptor antagonists (DORAs) are a new, potentially safer class of medications for insomnia.
Arianna Paolone +5 more
wiley +1 more source
Hip Fracture Risk of Lemborexant and Suvorexant in Comparison With Z‐Drugs: A Target Trial Emulation
ABSTRACT Background Lemborexant and suvorexant are widely used dual orexin receptor antagonists (DORAs) for the pharmacological treatment of insomnia. Although they are generally considered safer than benzodiazepine receptor agonists (Z‐drugs) regarding adverse events including hip fractures, evidence from direct comparisons remains limited. This study
Yuichiro Matsuo +5 more
wiley +1 more source
Hypocretin (orexin) regulation of sleep-to-wake transitions
The hypocretin (Hcrt), also known as orexin, peptides are essential for arousal stability. Here I discuss background information about the interaction of Hcrt with other neuromodulators, including norepinephrine and acetylcholine probed with optogenetics.
Luis eDe Lecea, Ramon eHuerta
doaj +1 more source

